LitAlert ~~ GeneLit.com

    • Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    • Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea AD, Swisher EM, Matulonis UA, Wulf GM. Mayer EL.
    • Clin Cancer Res. 2022 Feb 11:clincanres.3045.2021. doi: 10.1158/1078-0432.CCR-21-3045. Epub ahead of print.

    • Niraparib Related Pulmonary Embolism during the Treatment of BRCA Mutant Advanced Ovarian Cancer.
    • Wei Q, Chen D, Liu Y.
    • Front Oncol. 2022 Feb 11;10:853211. doi: 10.3389/fonc.2022.853211.

    • Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
    • Nie X, Chen X, Jiang Y, Zhong Y, Chen T, Cheng W.
    • Medicine (Baltimore). 2022 Feb 11;101(6):e28712. doi: 10.1097/MD.0000000000028712.

    • Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
    • Launonen IM, Lyytikäinen N, Casado J, Anttila EA, Szabó A, Haltia UM, Jacobson CA, Lin JR, Maliga Z, Howitt BE, Strickland KC, Santagata S, Elias K, D’Andrea AD, Konstantinopoulos PA, Sorger PK, Färkkilä A.
    • Nat Commun. 2022 Feb 11;13(1):835. doi: 10.1038/s41467-022-28389-3.

    • Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    • Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG, Lee JY.
    • Gynecol Oncol. 2022 Feb 10:S0090-8258(22)00086-5. doi: 10.1016/j.ygyno.2022.02.002. Epub ahead of print.